Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
51
Recruiting, any sponsor type, condition "plaque psoriasis"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed698
51 trials
Showing 1 to 25, recently updated first.
- A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque PsoriasisPivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06979453 · 366 participants (planned) · Start Dec 3, 2025 · Primary completion Oct 12, 2029
Drug: Deucravacitinib · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Phoenix, Arizona; Fountain Valley, California · 137 sites in all
- Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)Pivotal-lookingRecruiting
Instituto de Investigación Marqués de ValdecillaAcademic, hospital or other
NCT07611747 · 1,117 participants (planned) · Start Apr 22, 2026 · Primary completion Apr 22, 2031
Drug: High-intensity lipid-lowering therapy · For: Rheumatoid Arthritis (RA); Psoriatic Arthritis (PsA); Systemic Lupus Erythematosus (SLE) and 4 more
Sites: Elche, Spain; Orihuela, Spain; Sant Joan d'Alacant, Spain · 17 sites in all
South Valley UniversityAcademic, hospital or other
NCT07946497 · 105 participants (planned) · Start Oct 1, 2026 · Primary completion Oct 1, 2027
Drug: Methotrexate · For: Chronic Plaque Psoriasis; Psoriatic Arthritis
Sites: Qina, Egypt
- A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque PsoriasisPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07250802 · 210 participants (planned) · Start Dec 4, 2025 · Primary completion Jul 3, 2034
Drug: Zasocitinib; Placebo and 1 more · For: Plaque Psoriasis
Sites: Chula Vista, California; Fountain Valley, California; Hialeah, Florida · 38 sites in all
- A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque PsoriasisPivotal-lookingRecruiting
Chipscreen Biosciences, Ltd.Industry
NCT07129382 · 220 participants (planned) · Start Sep 8, 2025 · Primary completion Sep 18, 2027
Drug: CS32582 capsule(low dose) or matched placebo; CS32582 capsule(high dose) or matched placebo and 3 more · For: Plaque Psoriasis
Sites: Beijing, China; Chengde, China; Shijiazhuang, China · 11 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT06857942 · 200 participants (planned) · Start Mar 19, 2025 · Primary completion May 2028
Drug: Tirzepatide · For: Psoriasis; Overweight or Obesity
Sites: Phoenix, Arizona; Fountain Valley, California; Fremont, California · 38 sites in all
- Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07116967 · 3,040 participants (planned) · Start Sep 22, 2025 · Primary completion Jan 16, 2031
Drug: Deucravacitinib; Ustekinumab · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 411 sites in all
- A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07850310 · 132 participants (planned) · Start Oct 20, 2026 · Primary completion Dec 13, 2027
Drug: MK-8644; Placebo for MK-8644 · For: Psoriasis; Healthy
Sites: Melbourne, Australia
- A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque PsoriasisPivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT04772079 · 153 participants (planned) · Start Mar 23, 2021 · Primary completion Jan 1, 2029
Drug: Deucravacitinib · For: Plaque Psoriasis
Sites: Ciudad Autonoma de Buenos Aires, Argentina; Buenos Aires, Argentina; CABA, Argentina · 65 sites in all
Oruka Therapeutics, Inc.Industry
NCT07449702 · 240 participants (planned) · Start Feb 23, 2026 · Primary completion May 2030
Drug: ORKA-001 · For: Plaque Psoriasis
Sites: Phoenix, Arizona; North Little Rock, Arkansas; Fountain Valley, California · 39 sites in all
Hansoh BioMedical R&D CompanyIndustry
NCT07879885 · 390 participants (planned) · Start Jul 31, 2025 · Primary completion Mar 1, 2027
Drug: HS-20137 · For: Moderate-to-severe Plaque Psoriasis
Sites: Beijing, China
Xijing HospitalAcademic, hospital or other
NCT07780929 · 3 participants (planned) · Start Nov 17, 2025 · Primary completion Aug 30, 2026
Drug: XJH05 ointment; Calcipotriol ointment · For: Psoriasis; Psoriasis (PsO)
Sites: Xi'an, China
- Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?Recruiting
Centre Hospitalier Universitaire de NiceAcademic, hospital or other
NCT06742333 · 40 participants (planned) · Start Jul 22, 2025 · Primary completion Jul 22, 2028
Drug: Bimekizumab; Clobetasol · For: Psoriasis
Sites: Nice, France; Lyon, France; Marseille, France · 7 sites in all
Modern Research Associates, PLLCAcademic, hospital or other
NCT07725822 · 15 participants (planned) · Start Sep 15, 2026 · Primary completion Jul 2027
Drug: Roflumilast 0.3% topical cream · For: Chronic Plaque Psoriasis; Nail Psoriasis
Sites: Dallas, Texas
Istanbul Training and Research HospitalGovernment (non-federal)
NCT07844772 · 100 participants (planned) · Start Jun 11, 2026 · Primary completion Dec 2026
Drug: IL-17 Inhibitor Therapy; Conventional Systemic Therapy · For: Chronic Plaque-type Psoriasis
Sites: Istanbul, Turkey (Türkiye)
- Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque PsoriasisPivotal-lookingRecruiting
Vanda PharmaceuticalsIndustry
NCT07362017 · 300 participants (planned) · Start Feb 17, 2026 · Primary completion Aug 2028
Drug: Ponesimod · For: Moderate-to-severe Chronic Plaque Psoriasis
Sites: Glendale, Arizona; Fremont, California; Miami, Florida · 10 sites in all
NCT06888193 · 20 participants (planned) · Start Nov 5, 2025 · Primary completion Dec 31, 2027
Drug: Bimekizumab · For: Moderate to Severe Plaque Psoriasis; Psoriatic Arthritis; Axial Spondyloarthritis and 1 more
Sites: Santa Monica, California; South Miami, Florida; Boston, Massachusetts · 14 sites in all
- A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque PsoriasisPivotal-lookingRecruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT07724366 · 400 participants (planned) · Start Sep 2, 2026 · Primary completion Sep 2027
Drug: TQH3906 capsules; Deucravacitinib tablets 6 mg and 2 more · For: Psoriasis
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 45 sites in all
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07719530 · 60 participants (planned) · Start Aug 4, 2026 · Primary completion Dec 31, 2026
Drug: The SHR-1139 injection; placebo · For: Psoriasis
Sites: Guangzhou, China
Zealand PharmaIndustry
NCT07733089 · 32 participants (planned) · Start Jul 22, 2026 · Primary completion Apr 2027
Drug: ZP9830; Placebo · For: Plaque Psoriasis
Sites: Leiden, Netherlands
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07663331 · 30 participants (planned) · Start Jul 14, 2026 · Primary completion Feb 2028
Drug: TyboWe® Adalimumab Injection · For: Adult Non-infectious Uveitis
Sites: Tianjin, China
InventisBio Co., LtdIndustry
NCT07489885 · 75 participants (planned) · Start Jun 3, 2026 · Primary completion Aug 2027
Drug: D-2570 Tablet; Placebo Tablets · For: Psoriasis
Sites: Birmingham, Alabama; Phoenix, Arizona; Chula Vista, California · 20 sites in all
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque PsoriasisPivotal-lookingRecruiting
Zhejiang Wenda Pharma Technology LTD.Industry
NCT07672561 · 375 participants (planned) · Start Mar 18, 2026 · Primary completion Nov 30, 2026
Drug: Drug:WD-890; Drug: placebo · For: Moderate to Severe Plaque Psoriasis
Sites: Nanjing, China
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06701513 · 350 participants (planned) · Start Jan 29, 2025 · Primary completion Apr 30, 2028
Drug: Deucravacitinib · For: Psoriasis
Sites: Amiens, France; Angers, France; Argenteuil, France · 48 sites in all
- A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque PsoriasisPivotal-lookingRecruiting
InventisBio Co., LtdIndustry
NCT07326813 · 477 participants (planned) · Start Jan 12, 2026 · Primary completion Jul 12, 2027
Drug: D-2570 Tablet; BMS-986165 Tablet and 1 more · For: Plaque Psoriasis
Sites: Shanghai, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.